CClinicalTrials.gg
Active, not recruitingNCT05134454AF-SPICEUpdated Aug 5, 2026

Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events

An interventional study of Extended ECG investigation in Ischemic Stroke and TIA, sponsored by Karolinska Institutet. Active, not recruiting at 1 site in Sweden. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
3,300
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Study summary

Stroke is one of the leading causes behind death and permanent disability in adults. Atrial fibrillation (AF) is the most common clinical arrhythmia and its prevalence is steeply increasing with age. Atrial fibrillation is associated with a manifold increase in the risk for stroke.

It is considered important to investigate the heart rhythm in stroke survivors without previously known AF, because detection of AF will prompt a change in antithrombotic treatment with subsequent lowering of the risk of recurrent stroke.

There are so far very few studies on the prognostic impact of ECG investigations post stroke. Despite this knowledge gap, ECG investigation post stroke is given high priority in national and international guidelines.

Considerable clinical resources are currently invested in these ECG investigations without knowledge of its utility.

The investigators plan a nationwide, randomised, register-based study (RRCT) including patients aged at least 70 years receiving in-hospital care for stroke or TIA (Transient Ischemic Attack). Included patients will be randomised to standard investigation (1-2 days of ECG ) or extended ECG investigation (14 days of ECG performed at least twice). Patients diagnosed AF will be offered anticoagulation treatment. Long-term follow-up will be performed via swedish health care registers.

The result of this trial will have major impact on the ECG screening recommendations for patients who have had stroke, a large group of patients with dismal prognosis.

Read the detailed description

Purpose and aims

The purpose of the trial is to study the prognostic impact of ECG investigation after stroke or TIA.

The aim is to investigate if extended ECG screening after stroke as compared to standard ECG screening reduces the occurrence of the primary composite endpoint of stroke, death and intracranial bleeding in patients with stroke or transient ischemic attack (TIA). Secondary aims include effects on major bleeding, myocardial infarction, pacemaker implantation, atrial fibrillation prevalence, oral anticoagulation (OAC) treatment and cost effectiveness.

Survey of the field Ischemic stroke is one of the leading causes of mortality worldwide, and a major cause behind permanent disability in adults. Atrial fibrillation (AF) is the most prevalent permanent clinically relevant arrhythmia with a steeply increasing incidence with advancing age. Atrial fibrillation is also one of the strongest risk factors for stroke. The increased stroke risk associated with AF can be markedly reduced by OAC treatment.

Unfortunately, AF is paroxysmal and asymptomatic in a significant proportion of patients, leading to lower detection rates and a similar proportion of stroke survivors with an untreated risk factor and higher risk of stroke recurrence. For this reason, it is widely recommended to make ECG recordings in patients suffering from stroke and TIA in order to detect previously undiagnosed AF.

Despite this, no study so far has been reported to bring evidence on the benefit of ECG AF screening in terms of reduced stroke recurrence and mortality after a stroke event. However, several studies have reported the yield of new AF diagnosis in stroke/TIA patients using different ECG recording strategies in different populations.

The knowledge gap on the possible benefits and cost effectiveness of ECG investigation after stroke/TIA has led to a large variation in international recommendations, a situation bringing uncertainty among policy makers, the profession and patients. The variation in recommendations from different societies have unusual proportions. There is also a large variation in clinical practice between different stroke units in Sweden.

Furthermore, since the magnitude of the net benefit (or net harm) of the ECG investigation is not yet known, extensive clinical resources as well as patient effort are today put into these ECG investigations without knowing about the benefit for the patient or cost effectiveness.

Research Idea

The study will compare current standard ECG investigation after stroke/TIA with an extended ECG investigation strategy and compare long-term prognosis in terms of hard clinical endpoints among participants.

P: Patients aged at least 70 years treated in Swedish stroke units for ischemic stroke/TIA who after 24-48 hours of standard ECG investigation have shown no signs of atrial fibrillation

I: Extended ECG ambulatory recording, at least 2 separate recordings of 14 days each 2-4 months apart

C: standard Swedish ECG investigation, continuous ECG for 24-48 hours

O: Composite endpoint of recurrent stroke, all-cause mortality and intracerebral bleeding

For the year 2020, the mean age of Swedish stroke patients was 75 years, with a higher mean age among women. Incidence of AF is strongly related to age as confirmed in epidemiological studies and in screening studies. The selected cut-off age of 70 years for this study will include three fourths of stroke patients targeting those at highest risk for AF. However, higher age implies a risk for lower compliance to ECG recordings. This has been taken into account when choosing ECG device. Hence, the chosen cut-off age for inclusion is deemed to balance the yield of the ECG investigation, the benefit from OAC treatment and stroke risk if AF is detected and the expected level of compliance to procedures and treatment related to the study.

The ECG investigation in the control arm is based on the minimum recommendations for stroke care issued by the Swedish board of health and welfare. There are however several guidelines from international societies recommending higher ambitions for this investigation, i.e longer ECG recordings. Several Swedish stroke units are implementing ECG investigations after stroke/TIA with ambitions higher than those stated by national minimum recommendations, assuming that these investigations will give more benefit to the patient. The study design is calculated to give a marked difference between the control and intervention groups to overcome the possible problem with an underpowered result reported from a previous study in the field.

Plans and methods for pilot study The pilot study will engage five to six patient-including stroke units which are already recruited. The pilot study is planned to include 200-300 patients with the aim to evaluate feasibility of study management, patient inclusion, inclusion rate, ECG recordings, flow of ECG data and short-term follow-up of positive ECG findings.

Parallel to the pilot study, a comprehensive, digital survey on ECG investigation practice covering all Swedish stroke units will be undertaken. This survey will be sent to the stroke units commencing in september 2021. The outcome of the survey will give a complete and up-to-date view of clinical practice and a possibility to identify suitable sites for the main trial.

During 2020, there were 28 000 patients included in national stroke register for stroke or TIA and three fourths of these patients were aged 70 years or older. The pilot and main study are planned to include 3300 patients during 2021-2024.

02

Conditions studied

  • Ischemic Stroke
  • TIA

Keywords

  • stroke
  • TIA
  • atrial fibrillation
  • ECG
  • oral anticoagulation
03

In context

Ischemic Stroke

2,595 studies on the registry are indexed under Ischemic Stroke; 932 are open to participants now.

This study's planned enrollment of 3,300 is above the median of 120 across 1,754 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged ≥ 70 years
  • A diagnosis of ischemic stroke or TIA within 14 days from inclusion.

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed atrial fibrillation
  • Contraindication to oral anticoagulant treatment according to Summary of Product Characteristics.
  • Indication for anticoagulant treatment other than atrial fibrillation, e.g. venous thromboembolism or mechanical heart valve prosthesis
  • Dual antiplatelet therapy not interchangeable to oral anticoagulation
  • Patients with pacemaker, implantable cardioverter defibrillator or implantable cardiac monitor.
  • Patients who, according to the investigator, will not be able to comply with the study protocol.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,300 participants (estimated)

Study arms

  • Experimental
    Extended ECG investigation

    Participants will undergo 0-48 hours of continuous ECG recording and at least two long-term continuous ambulatory ECG recordings with a duration of 14 days each.

    Diagnostic Test: Extended ECG investigation

  • No intervention
    Standard of care

    Participants will undergo 24-48 hours of continuous ECG recording.

Interventions

  • Diagnostic testExtended ECG investigation

    At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.

06

What researchers measure

Primary outcomes

  1. Composite of stroke, death and intracerebral bleeding

    Stroke is defined as the occurence of International Classification of Diseases (ICD) 10 codes I63 in swedish health care registers. Intracranial bleeding is defined as the occurence of ICD 10 codes I61 in swedish health care registers. Mortality is defined as death reported by the swedish registers on cause of death.

    Time frame: at least 36 months of follow-up (study event driven)

Secondary outcomes

  1. Individual components of the primary endpoint

    Stroke is defined as the occurence of ICD 10 codes I63 in swedish health care registers. Intracranial bleeding is defined as the occurence of ICD 10 codes I61 in swedish health care registers. Mortality is defined as death reported by the swedish registers on cause of death.

    Time frame: at least 36 months of follow-up (study event driven)

  2. Major bleeding

    Defined as the occurence of any of the following ICD 10 codes in swedish health care registers: I60, I62, I850, I983, K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K284, K286, K290, K625, K661, K920-921, K922, N02, R04, R58, T810, D629, D50-64,D65-69

    Time frame: at least 36 months of follow-up (study event driven)

  3. Myocardial infarction

    Defined as the occurence of any of the following ICD 10 codes in swedish health care registers: I21

    Time frame: at least 36 months of follow-up (study event driven)

  4. Pacemaker implantation

    Defined as the occurence of any of the following measures in swedish health care registers: FPE00-96

    Time frame: at least 36 months of follow-up (study event driven)

  5. Anticoagulation treatment

    Defined as the occurence of any of the following ICD 10 codes in swedish health care registers: Z921 or the prescription of any of the following Anatomical Therapeutic Chemical Classification System (ATC) codes: B01AA, B01AE, B01AF

    Time frame: at least 36 months of follow-up (study event driven)

  6. Atrial fibrillation prevalence

    The proportion of participants with the ICD 10 code I48 in swedish health care registers divided by the total number of participants.

    Time frame: at least 36 months of follow-up (study event driven)

  7. Adherence to long-term ECG recording

    For each participant, the duration of the actual ECG signal acquired during long-term ECG recording will be divided by the theoretical maximum duration of ECG signal which is 14 days. The resulting proportion is the adherence. Example: A participant discontinues the ECG recording after 7 days and the investigators will receive 7 days of ECG of the expected 14 days of ECG signal for interpretation. In this case, adherence will be 7/14 = 50%.

    Time frame: at least 36 months of follow-up (study event driven)

  8. Incidence of other prognostic arrhythmia during long-term ECG recording.

    The incidence of atrioventricular block degree 2 or 3, ventricular tachycardia, \>5% premature ventricular ectopic beats, pauses \> 3 seconds and bradycardia slower than 40/min and during long-term ECG recording.

    Time frame: at least 36 months of follow-up (study event driven)

07

Study locations

1 site
  • Karolinska Institutet Danderyds University Hospital
    Stockholm, Stockholm County 18288, Sweden
08

References and documents

Publications

  • Engdahl J, Straat K, Isaksson E, Rooth E, Svennberg E, Norrving B, Euler MV, Hellqvist K, Gu W, Strom JO, Sjalander S, Eriksson M, Asberg S, Wester P. Multicentre, national, investigator-initiated, randomised, parallel-group, register-based superiority trial to compare extended ECG monitoring versus standard ECG monitoring in elderly patients with ischaemic stroke or transient ischaemic attack and the effect on stroke, death and intracerebral bleeding: the AF SPICE protocol. BMJ Open. 2023 Nov 23;13(11):e073470. doi: 10.1136/bmjopen-2023-073470. PubMed 37996238 ↗

Individual participant data

Plan to share: Yes — Individual participant datat will be shared upon reasonable request.

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05134454
Lead sponsor
Karolinska Institutet
Collaborators
Uppsala University, Örebro University, Sweden, Lund University, Umeå University, The Swedish Research Council, Swedish Heart Lung Foundation
Responsible party
Johan Engdahl (Associate Professor, Senior consultant, Karolinska Institutet) — Principal investigator
First posted
Nov 26, 2021
Start date
Jan 20, 2022
Primary completion
Dec 31, 2025
Completion
Dec 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Johan Engdahl, MD, PhD
study chair · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion